NO20041494L - Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form - Google Patents

Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form

Info

Publication number
NO20041494L
NO20041494L NO20041494A NO20041494A NO20041494L NO 20041494 L NO20041494 L NO 20041494L NO 20041494 A NO20041494 A NO 20041494A NO 20041494 A NO20041494 A NO 20041494A NO 20041494 L NO20041494 L NO 20041494L
Authority
NO
Norway
Prior art keywords
sites
insulin
hisb
insulin hexamer
novel ligands
Prior art date
Application number
NO20041494A
Other languages
English (en)
Norwegian (no)
Inventor
Palle Jakobsen
Niels Christian Kaarsholm
Peter Madsen
Helle Birk Olsen
Soren Ostergaard
Svend Ludvigsen
Anders Klarskov Petersen
Dorte Bjerre Steensgaard
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of NO20041494L publication Critical patent/NO20041494L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C07D249/18—Benzotriazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
NO20041494A 2001-09-14 2004-04-13 Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form NO20041494L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200101337 2001-09-14
US32392501P 2001-09-21 2001-09-21
DKPA200201066 2002-07-05
US39605102P 2002-07-10 2002-07-10
PCT/DK2002/000595 WO2003027081A2 (en) 2001-09-14 2002-09-13 NOVEL LIGANDS FOR THE HisB10 Zn2+ SITES OF THE R-STATE INSULIN HEXAMER

Publications (1)

Publication Number Publication Date
NO20041494L true NO20041494L (no) 2004-04-13

Family

ID=27439845

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041494A NO20041494L (no) 2001-09-14 2004-04-13 Nye ligander for HisB 10 Zn2+ -setene i insulinheksameren i R-form

Country Status (15)

Country Link
US (1) US7879893B2 (de)
EP (1) EP1429763B1 (de)
JP (1) JP4554207B2 (de)
CN (1) CN1558762A (de)
AT (1) ATE363278T1 (de)
BR (1) BR0212522A (de)
CA (1) CA2460541A1 (de)
CZ (1) CZ2004313A3 (de)
DE (1) DE60220424T2 (de)
ES (1) ES2288195T3 (de)
HU (1) HUP0401492A3 (de)
MX (1) MXPA04002404A (de)
NO (1) NO20041494L (de)
PL (1) PL369119A1 (de)
WO (1) WO2003027081A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070060606A1 (en) * 1999-10-07 2007-03-15 Robertson Harold A Compounds and methods for modulating phosphodiesterase 10A
US7087631B2 (en) * 2002-07-18 2006-08-08 Inotek Pharmaceuticals Corporation Aryltetrazole compounds, and compositions thereof
US7078423B2 (en) * 2002-07-18 2006-07-18 Inotek Pharmaceuticals Corporation 5-Aryltetrazole compounds, compositions thereof, and uses therefor
US20040063098A1 (en) * 2002-09-26 2004-04-01 Hargreaves John S. Methods for producing multilayer ligand arrays
EP1597255A1 (de) * 2002-11-13 2005-11-23 Rigel Pharmaceuticals, Inc. Rhodanin-derivate und sie enthaltende pharmazeutische zusammensetzungen
WO2004056347A2 (en) * 2002-12-20 2004-07-08 Novo Nordisk A/S Pharmaceutical compositions comprising insulin and legends of insulin hexamer
US20050065066A1 (en) * 2002-12-20 2005-03-24 Kaarsholm Niels Christian Stabilised insulin compositions
US7781464B2 (en) 2003-01-17 2010-08-24 Bexel Pharmaceuticals, Inc. Heterocyclic diphenyl ethers
US7521465B2 (en) * 2003-01-17 2009-04-21 Bexel Pharmaceuticals, Inc. Diphenyl ether derivatives
JP2007523842A (ja) * 2003-03-11 2007-08-23 ノボ ノルディスク アクティーゼルスカブ 酸安定化されたインスリンを含有する薬学的製剤
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
BRPI0411691A (pt) * 2003-07-02 2006-12-26 Teva Gyogyszergyar Reszvenytar l-lisina de aztreonam e seus métodos de preparação
US7087576B2 (en) 2003-10-07 2006-08-08 Bexel Pharmaceuticals, Inc. Dipeptide phenyl ethers
US7037927B2 (en) * 2003-10-16 2006-05-02 Abbott Laboratories Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor
ES2369895T3 (es) 2003-12-03 2011-12-07 Novo Nordisk A/S Insulina monocatenaria.
EP2261218B1 (de) 2004-05-26 2013-04-03 Eisai R&D Management Co., Ltd. Composé imidazole pour l'utilisation comme produit intermédiaire dans la production de composés cinnamide
ES2542228T3 (es) * 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
WO2006005683A1 (en) * 2004-07-09 2006-01-19 Novo Nordisk A/S Phamaceutical preparations comprising insulin
MX2007001431A (es) * 2004-08-05 2007-04-02 Hoffmann La Roche Derivados de indol, de indazol o de indolina.
US20080280814A1 (en) * 2004-09-17 2008-11-13 Novo Nordisk A/S Pharmaceutical Compositions Containing Insulin and Insulinotropic Peptide
WO2006035954A1 (en) * 2004-09-28 2006-04-06 Otsuka Pharmaceutical Co., Ltd. Carbostyril compound
KR20070083781A (ko) 2004-10-26 2007-08-24 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물의 비정질체
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
TW200800978A (en) * 2006-03-23 2008-01-01 Otsuka Pharma Co Ltd Carbazole compound
JP5191155B2 (ja) * 2006-03-27 2013-04-24 大塚製薬株式会社 カルボスチリル化合物からなる医薬
TW200848054A (en) 2007-02-28 2008-12-16 Eisai R&D Man Co Ltd Two cyclic oxomorpholine derivatives
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
AR068121A1 (es) 2007-08-31 2009-11-04 Eisai R&D Man Co Ltd Compuestos multiciclicos para tratar enfermedades neurodegenerativas
CN104125948A (zh) 2012-02-21 2014-10-29 拜耳知识产权有限责任公司 具有除草活性的4-硝基-取代的n-(四唑-5-基)芳基羧酸酰胺、n-(三唑-5-基)芳基羧酸酰胺以及n-(1,3,4-噁二唑-2-基)芳基羧酸酰胺
EP2844260A4 (de) * 2012-04-30 2016-06-29 Anderson Gaweco Ror-modulatoren und deren verwendungen
KR101942752B1 (ko) * 2012-11-05 2019-01-28 주식회사 엘지화학 Gpr120 효능제로서의 티오아릴 유도체
JP6156845B2 (ja) * 2014-03-04 2017-07-05 株式会社島津製作所 マトリックス支援レーザ脱離イオン化質量分析用マトリックス
CA2968884A1 (en) * 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
US10501413B2 (en) 2015-03-23 2019-12-10 University Of Miami Inhibitors of the Notch transcriptional activation complex and methods for use of the same
RU2018132559A (ru) 2016-02-16 2020-03-17 Массачусетс Инститьют Оф Текнолоджи Связывающие молекулы для max в качестве модуляторов myc и их применения
WO2018005660A1 (en) * 2016-06-28 2018-01-04 University Of Kentucky Research Foundation Prostaglandin e synthase inhibitors and methods for utilizing the same
EP3558992A4 (de) * 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. Aktivator von trek (twik-assoziierten k+ kanälen)-kanälen
WO2019178439A1 (en) * 2018-03-16 2019-09-19 The Board Of Regents Of The University Of Oklahoma Agonists of peroxisome proliferator-activated receptor alpha and methods of use
US12473312B2 (en) 2018-03-16 2025-11-18 The Board Of Regents Of The University Of Oklahoma Agonists of peroxisome proliferator-activated receptor alpha (PPAR+60 ) and methods of use
EP3953342B1 (de) 2019-04-11 2025-09-24 University of Miami Verbesserte inhibitoren des notch-transkriptionsaktivierungskomplexes und verfahren zur verwendung davon
WO2024226603A1 (en) * 2023-04-24 2024-10-31 Regents Of The University Of Minnesota Therapeutic compounds
CN121135615B (zh) * 2025-11-18 2026-04-14 江西初源新材料有限公司 一种用于感光树脂组合物的蒽甲硫代水杨酸及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DOP1982004086A (es) * 1981-08-27 1988-03-22 Lilly Co Eli Formula farmaceutica que comprende insulina humana y proinsulina humana
US5646120A (en) * 1990-10-24 1997-07-08 Allelix Biopharmaceuticals, Inc. Peptide-based inhibitors of HIV replication
US5830999A (en) 1995-01-26 1998-11-03 Regents Of The University Of California Stabilization of insulin through ligand binding interations
WO2000029013A1 (en) * 1998-11-18 2000-05-25 Novo Nordisk A/S Stable aqueous insulin preparations without phenol and cresol

Also Published As

Publication number Publication date
US7879893B2 (en) 2011-02-01
EP1429763A2 (de) 2004-06-23
EP1429763B1 (de) 2007-05-30
JP2005508335A (ja) 2005-03-31
JP4554207B2 (ja) 2010-09-29
DE60220424T2 (de) 2008-03-06
WO2003027081A3 (en) 2004-03-25
WO2003027081A2 (en) 2003-04-03
CN1558762A (zh) 2004-12-29
HUP0401492A2 (hu) 2004-11-29
BR0212522A (pt) 2004-08-10
CA2460541A1 (en) 2003-04-03
ATE363278T1 (de) 2007-06-15
US20030229120A1 (en) 2003-12-11
PL369119A1 (en) 2005-04-18
CZ2004313A3 (cs) 2004-07-14
HUP0401492A3 (en) 2008-05-28
MXPA04002404A (es) 2004-05-31
ES2288195T3 (es) 2008-01-01
DE60220424D1 (de) 2007-07-12

Similar Documents

Publication Publication Date Title
PL369119A1 (en) Novel ligands for the hisb10 zn2+ sites of the r-state insulin hexamer
DE60237828D1 (de) Neue verbindungen
PT1086124E (pt) Ciclosporinas novas
GB2431404A (en) Peptide
BR0210078A (pt) Composto, uso do mesmo, e, formulação farmacêutica
ATE481987T1 (de) Verfahren zur radiofluoridierung von biologisch aktiven vektoren
DE69326250D1 (de) Neuropeptide y antagoniste
FI924503A0 (fi) Foerbaettrade trombininhibitorer
DE69837324D1 (de) Behandlung der multiplen sklerose durch einnahme von copolymer-1
BR0312889A (pt) Polipeptìdeo t20 peguilado
DE60231825D1 (de) Behandlung von infektionen verursacht von mikroorganismen
AU2003291972A8 (en) Pharmaceutical compositions comprising insulin and legends of insulin hexamer
WO2001052900A3 (en) Novel orthogonally protected amino acid chelators for biomedical applications
EA200200807A1 (ru) Аминокислотные соединения и их применение в качестве ингибиторов nep, ace и ece
DK1127064T3 (da) Hidtil ukendte aminosyresekvenser, DNA, der koder for aminosyresekvenserme, antistoffer, der er rettet mod sådanne sekvenser, og forskellige anvendelser deraf
EP1310490A4 (de) Gpr14-antagonisten
DK1180094T3 (da) Kondenserede polycykliske aminosyrer som farmaceutiske midler
HRP20020703B1 (en) Memno peptides, a process for their preparation and their use
ATE284703T1 (de) Kristallmodifikation eines cyclischen depsipeptids mit besserer wirksamkeit
IL159493A0 (en) Pharmaceutical formulation containing an ltb4 antagonist
WO2003048187A3 (en) Peptides and use thereof in therapeutic agents against hiv infection
CY1105363T1 (el) Ν,ν΄-διυποκατεστημενες ενωσεις πιπepαζινης και η χρηση τους σαν αναλγητικα μεσα
DE60002694D1 (de) Verwendung von copolymeren abgeleitet von polyamiden als geliermittel für wenig polare verbindungen
WO2003089472A3 (en) Anti-nls scfv and peptides and uses thereof in nuclear import inhibition
WO2003029290A1 (en) Drug transporter and use thereof

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application